147 related articles for article (PubMed ID: 7701804)
1. Effect of terminal (dry) heat treatment on non-enveloped viruses in coagulation factor concentrates.
Hart HF; Hart WG; Crossley J; Perrie AM; Wood DJ; John A; McOmish F
Vox Sang; 1994; 67(4):345-50. PubMed ID: 7701804
[TBL] [Abstract][Full Text] [Related]
2. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the inactivation of canine and bovine parvovirus by freeze-drying and dry-heat treatment in two high purity factor VIII concentrates.
Roberts PL; Hart H
Biologicals; 2000 Sep; 28(3):185-8. PubMed ID: 10964445
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of hepatitis A virus by heat treatment in aqueous solution.
Murphy P; Nowak T; Lemon SM; Hilfenhaus J
J Med Virol; 1993 Sep; 41(1):61-4. PubMed ID: 8228940
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
6. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.
Santagostino E; Mannucci PM; Gringeri A; Azzi A; Morfini M; Musso R; Santoro R; Schiavoni M
Transfusion; 1997 May; 37(5):517-22. PubMed ID: 9149778
[TBL] [Abstract][Full Text] [Related]
7. Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses. The Ad Hoc Study Group of the Fondazione dell'Emofilia.
Mariani G; Di Paolantonio T; Baklaya R; Morfini M; Mannucci PM
Transfusion; 1993 Oct; 33(10):814-8. PubMed ID: 8236421
[TBL] [Abstract][Full Text] [Related]
8. Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C.
Dichtelmüller H; Rudnick D; Breuer B; Kotitschke R; Kloft M; Darling A; Watson E; Flehmig B; Lawson S; Frösner G
Biologicals; 1996 Jun; 24(2):125-30. PubMed ID: 8889059
[TBL] [Abstract][Full Text] [Related]
9. Inactivation kinetics of model and relevant blood-borne viruses by treatment with sodium hydroxide and heat.
Borovec S; Broumis C; Adcock W; Fang R; Uren E
Biologicals; 1998 Sep; 26(3):237-44. PubMed ID: 10208725
[TBL] [Abstract][Full Text] [Related]
10. Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate.
Lemon SM; Murphy PC; Smith A; Zou J; Hammon J; Robinson S; Horowitz B
J Med Virol; 1994 May; 43(1):44-9. PubMed ID: 8083647
[TBL] [Abstract][Full Text] [Related]
11. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII.
Roberts PL; Dunkerley C; McAuley A; Winkelman L
Vox Sang; 2007 Jan; 92(1):56-63. PubMed ID: 17181591
[TBL] [Abstract][Full Text] [Related]
12. Determination of the inactivation kinetics of hepatitis A virus in human plasma products using a simple TCID50 assay.
Barrett PN; Meyer H; Wachtel I; Eibl J; Dorner F
J Med Virol; 1996 May; 49(1):1-6. PubMed ID: 8732864
[TBL] [Abstract][Full Text] [Related]
13. Successful clinical use of a plasma-derived, dual virus inactivated factor VII concentrate incorporating solvent-detergent and dry heat treatment.
Smith MP; Rice KM; Savidge GF
Thromb Haemost; 1997 Feb; 77(2):406-7. PubMed ID: 9157608
[No Abstract] [Full Text] [Related]
14. Determination of adequate moisture content for efficient dry-heat viral inactivation in lyophilized factor VIII by loss on drying and by near infrared spectroscopy.
Savage M; Torres J; Franks L; Masecar B; Hotta J
Biologicals; 1998 Jun; 26(2):119-24. PubMed ID: 9811517
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII concentrate.
Hilfenhaus J; Nowak T
Vox Sang; 1994; 67 Suppl 1():62-6. PubMed ID: 8091740
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of two viral inactivation methods for the preparation of safer factor VIII and factor IX concentrates.
Heldebrant CM; Gomperts ED; Kasper CK; McDougal JS; Friedman AE; Hwang DS; Muchmore E; Jordan S; Miller R; Sergis-Davenport E
Transfusion; 1985; 25(6):510-5. PubMed ID: 3934800
[TBL] [Abstract][Full Text] [Related]
17. Effect of monosaccharides during severe dry heat treatment of coagulation factor VIII concentrates.
Knevelman A; de Wit HJ; Griffin B; Hart H; McIntosh RV
Vox Sang; 1994; 66(2):96-103. PubMed ID: 8184599
[TBL] [Abstract][Full Text] [Related]
18. Virus inactivation in albumin by a combination of alkali conditions and high temperature.
Roberts PL; More J; Rott J; Lewin D
Biologicals; 2011 Mar; 39(2):67-72. PubMed ID: 21333548
[TBL] [Abstract][Full Text] [Related]
19. Testing thermal resistance of viruses.
Sauerbrei A; Wutzler P
Arch Virol; 2009; 154(1):115-9. PubMed ID: 19039515
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a new LightCycler reverse transcription-polymerase chain reaction infectivity assay for detection of human parvovirus B19 in dry-heat inactivation studies.
Prikhod'ko GG; Vasilyeva I; Reyes H; Wong S; Brown KE; Jameson T; Busby TF
Transfusion; 2005 Jun; 45(6):1011-9. PubMed ID: 15935001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
